DelMar Pharmaceuticals Reports Full

DelMar Pharmaceuticals Reports Full

Compliance with Nasdaq Listing Criteria

SAN DIEGO, California,

September 9, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"),

a biopharmaceutical company focused on the development of novel cancer therapies, today announced that on September 6, 2019,

the Company was formally notified by The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained full compliance

with all criteria for continued listing on The Nasdaq Capital Market, including the applicable stockholders' equity requirement.

Nasdaq's determination follows the previously disclosed $6.7 million in net proceeds from the underwritten offering completed

Pharmaceuticals, Inc.

Located in San Diego, California, DelMar

is focused on the development and commercialization of new therapies for cancer patients who have limited or no treatment options.

By focusing on understanding tumor biology and mechanisms of treatment resistance, the Company identifies biomarkers to personalize

new therapies in indications where patients are failing, or are unable to tolerate, standard-of-care treatments.

The Company's current pipeline is

based around VAL-083, a "first-in-class", small-molecule chemotherapeutic with a novel mechanism of action that has

demonstrated clinical activity against a range of cancers, including central nervous system, ovarian and other solid tumors (e.g.

NSCLC, bladder cancer, head & neck) in U.S. clinical trials sponsored by the National Cancer Institute (NCI). Based on DelMar's

internal research programs and these prior NCI-sponsored clinical studies, the Company is conducting clinical trials to support

the development and commercialization of VAL-083 to solve significant unmet medical needs.

VAL-083 is being studied in two collaborator-supported,

biomarker-driven Phase 2 clinical trials for MGMT-unmethylated GBM. Overcoming MGMT-mediated resistance represents a significant

unmet medical need in the treatment of GBM. In addition, DelMar has announced the allowance of a separate IND for VAL-083 as a

potential treatment for platinum-resistant ovarian cancer.

Further information on DelMar's clinical

trials can be found on clinicaltrials.gov: https://www.clinicaltrials.gov/ct2/results?cond=&term=val-083&cntry1=&state1=&recrs

For additional information, please visit http://delmarpharma.com/;

or contact DelMar Pharmaceuticals Investor Relations: ir@delmarpharma.com / (604) 629-5989.

Safe Harbor Statement

Any statements contained in this press release that do not describe

historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform

Act of 1995, including statements regarding the continued listing of the Company's common stock on the Nasdaq Capital Market. Any

forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties.

The factors that could cause actual future results to differ materially from current expectations include, but are not limited

to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the

expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for

the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization;

and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies.

These and other factors are identified and described in more detail in the Company's filings with the SEC, including, the

Company's Annual Report on Form 10-K for the year ended June 30, 2018, the Company's Quarterly Reports on Form 10-Q,

and the Company's Current Reports on Form 8-K.